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A b s t r a c t 
This paper will explore the nature of psychiatric co-morbidities in people with an intellectual disability (ID) who 
have epilepsy. The complexity of clinical presentations and associated co-morbidities require thorough 
assessment utilising both neurological and psychiatric skills. The neurologist plays a central role in the 
management of epilepsy in people with ID and therefore requires basic competencies in the assessment of 
neuropsychiatric co-morbidities. This is key to liaison with other specialist services to ensure individuals 
receive holistic person centred care. 
 
1. Introduction 
This paper will explore the nature of psychiatric comorbidities in people with an intellectual disability (ID) who 
have epilepsy. The complexity of clinical presentations and associated comorbidities means that thorough 
assessment needs both neurological and psychiatric 
skills. 
There is a strong relationship between epilepsy and ID, with the prevalence of epilepsy increasing with severity 
of ID. A pooled meta-analysis of people with ID estimates an overall prevalence of epilepsy of 22% [1]. 
Epilepsy is associated with high levels of comorbidity including a wide range of neurological and psychiatric 
disorders, and the prevalence of common psychiatric disorders is higher in people with epilepsy than in the 
general population (Table 1). This includes the population with ID [9], particularly those with active epilepsy 
[10]. Psychiatric symptoms may be directly linked to seizure activity and present periictally (preictal, ictal, or 
postictal) or temporally independent of seizure occurrence (interictally). 
Neuropsychiatric symptoms have a detrimental impact upon quality of life [2]. They may be explained by 
common risk factors, underlying anatomical problems, pathological processes that interact both directly and 
indirectly or the wider impact of epilepsy as a chronic condition [11,12]. 
A major challenge in attempting to identify the incidence of psychiatric diagnoses for people with epilepsy is 
sampling a representative population. Sample populations are often derived from specialist epilepsy centers 
with complex disease and higher rates of neuropsychiatric 
comorbidities. Comparing epidemiological studies is difficult, owing to methodological differences, especially 
when specifically considering epilepsy and ID. Studies are limited with numerous confounding factors, 
variability in assessment tools, and heterogeneous populations [13]. 
 
2. Psychiatric comorbidities in people with epilepsy and ID Up to one-third of people with epilepsy and ID may 
have a diagnosable psychiatric illness, far above the rate observed in a comparable sample of people with ID 
alone [14]. A recent systematic review examined neuropsychiatric comorbidities in people with epilepsy and 
ID. People with epilepsy and ID show higher levels of mood dysregulation, negative mood symptoms, and a 
lack of empathy [13]. In contrast to other research, there is some evidence that people with epilepsy and 
ID have less psychiatric symptoms when compared with people with ID alone. Investigators suggest that this 
may be related to the effect of anticonvulsant medication [15]. 
There are a number of risk factors for psychiatric comorbidities in people with epilepsy and ID (see Table 2). 
These include genotype, autistic features, ID severity, and antiepileptic drug (AED) prescription [16]. Both 
seizure severity and frequency have consistently been identified as independent risk factors for psychiatric 
symptoms in people with epilepsy and ID [14]. 
 
 
People with epilepsy and ID should not be excluded from epilepsy surgical interventions (National Institute for 
Health and Care Excellence [NICE], CG137) [17]. However, surgical interventions for people with epilepsy and 
ID remain lower than those without ID[18]. Improvements in behavioral outcomes measures have been 
observed a year after epilepsy surgery [19]. There is evidence to suggest that epilepsy surgery actually 
improves both behavioral and cognitive functioning in specific subpopulations of people with epilepsy and ID 
[16]. 
The presence of epilepsy in the ID population is also associated with an overall increased risk of behavioral 
problems [20]. Behavioral changes that commonlymanifest in peoplewith epilepsy and ID include aggression, 
self-injurious behavior (SIB), disruptive or destructive behavior, and stereotyped behaviors [21]. Behavioral 
disorders are multifactorial and may be influenced by a wide range of environmental factors. A number of 
genetic syndromes (Angelman, Cornelia de Lange, Cri du Chat, Fragile X, Prader–Willi, Smith-Magenis) are 
associated with specific and nonspecific behavioral changes including increased aggression [22]. The severity 
of intellectual disability itself is associated with awide range of behavioral problems including hyperactivity and 
stereotypical behavior [14,23]. However, there is evidence to suggest that when confounders are controlled 
particularly psychiatric comorbidities, increased rates of aggression become statistically insignificant 
[24]. 
 
 
 
2.1. Autism 
Autism or autism spectrum disorder (ASD) is a common comorbidity found in association with epilepsy and ID 
[25] with an estimated prevalence of over 25% [26]. Autism and ID is associated with increased stereotyped 
behaviors, SIB, property destruction, aggression, anxiety, irritability, and impaired attention and hyperactivity 
[27,28]. Autism is also associated with an impairment in overall functioning, a known risk factor for behavior 
problems, suggesting comorbid neurodevelopmental disorders increase the risk of both behaviour problems 
and psychopathology [29,30]. 
 
2.2. Antiepileptic drugs (AEDs) 
For some individuals, certain AEDs may be associated with adverse neuropsychiatric symptoms (Table 3). 
However, improvement in seizure control with AEDs can lead to improvement in the cognitive and behavioral 
effects of epilepsy [32,33]. It has been consistently shown that those individuals with preexisting psychiatric 
comorbidities are more likely to develop psychiatric adverse effects with AEDs. It is possible that psychiatric 
side effects may be less common with AEDs that block sodium channels [34]. 
There is limited evidence evaluating the impact of AEDs in the population with epilepsy and ID. A Cochrane 
review shows that many of the investigations conducted in this population are low powered, uncontrolled, 
retrospective, and use unreliable measures of behavior [35]. Behavioral and cognitive side effects of AEDs in 
this population require further investigation with robust methodology and appropriate assessment measures 
[35]. 
Antiepileptic drugs can be used to treat a wide range of psychiatric and behavioral disorders (Table 4). The 
mood stabilizing properties of valproate, lamotrigine, and carbamazepine have been well-established and they 
are routinely used as treatment as an acute or prophylactic agent in affective disorders [38]. A systematic 
review has demonstrated the wide range of psychiatric conditions treated with gabapentin, ranging from 
anxiety disorders to dependence syndromes [39]. 
 
3. Managing psychiatric comorbidities — key components 
 
3.1. Assessment 
 
Assessment and treatment of psychiatric comorbidities can be complex because of the wide range of etiologies 
and comorbidities in people with epilepsy and ID. There are consensus guidelines for the management of 
behavioral disorder in people with epilepsy and ID (Table 5) [16, 40]. The assessment process should adopt a 
person-centered approach and aim to identify whether changes in behavior or psychiatric symptoms are 
directly related to the epilepsy or influenced by its management. 
 
 
It is important to exclude potentially reversible causes of new onset psychiatric symptoms in people with 
epilepsy. These include delirium, which typically has a fluctuating course, inattention, and disordered thinking 
or altered level of consciousness. Delirium can be precipitated by infections, metabolic disturbances, toxins, 
hypoxia, urinary retention, and constipation [42]. Nonconvulsive status epilepticus can cause behavioral 
change as well as altered awareness, and there should be a low threshold for requesting an 
electroencephalogram (EEG) and/or considering a trial of benzodiazapines if this is considered. Other 
diagnoses to consider include alcohol and illicit drugs, limbic encephalitis, and neurodegenerative diseases 
[42]. Depending on the initial assessment, blood tests and/or brain imaging might be necessary if some of 
these conditions are suspected. 
 
 
 
 
 
3.1.1. Defining the behavior 
A video-EEG can be useful for people with epilepsy and ID to help differentiate seizure activity from behavior 
[43]. This, along with detailed information gathering and observations, will help discriminate seizures from 
other complex behaviors or stereotyped movements [44]. 
 
3.1.2. Psychiatric symptoms in people with an intellectual disability 
The presentation of psychiatric symptoms in the population with ID can be complex and as heterogeneous as 
the population itself. This complexity may be increased by common comorbidities including 
neurodevelopmental disorders such as autism. The presence of communication difficulties alters our approach 
to assessment and diagnosis, and may diminish reliability. Therefore, attempting to apply objective and 
subjective diagnostic criteria to psychiatric symptoms is not straight forward. 
In order to fully understand behavior, a detailed functional analysis may be required. This process will often 
require the input of specialist multidisciplinary learning disability teams to provide a holistic approach. This 
process is inevitably longer but needs to take into account all potential variables that may influence behavior 
and symptoms including environmental, social, sensory, emotional, and biological factors. Work may be 
required from a number of specialists from within the team including speech and language therapy, 
occupational therapy, nursing, and psychology in order to reach an accurate formulation of any individual's 
needs. There are specific evidence-based adapted diagnostic criteria available for people with ID that may help 
with the assessment process [45]. 
Following this assessment there will be a clearer indication as to whether the behavior is related to seizures, 
epilepsy treatment, or other factors (Table 5). There are validated tools available to help inform the 
assessment process including the Aberrant Behavior Checklist (ABC) [46]. 
 
3.2. Treatment 
The NICE clinical guidelines on epilepsies (CG137) [17] suggest the same treatment for people with 
ID as the general population. However, there is no clear guidance on the specific complexities 
associated with epilepsy and ID. The Royal College of Psychiatrists has produced a technical paper 
advising on the prescription of AEDs in epilepsy for people with ID [47], based on current evidence. 
The College Report also includes considerations around the treatment of psychiatric comorbidities. 
 
3.2.1. AED-related neuropsychiatric symptoms 
The consensus guidelines [40] produced by the Health Special Interest Group of the International association 
for the Scientific Study of Intellectual Disability (IASSIDD), on the management of epilepsy in adults with ID, 
consider the impact of AEDs on behavior and cognition a priority. It is recommended that prior to the 
introduction of an AED, baseline assessments of behavior and cognition are completed, using validated tools, 
for later comparison [48]. 
Some AEDs have neuropsychiatric side effect profiles (see Table 5), and these should be borne in mind before 
they are prescribed to people with epilepsy and ID. For example phenobarbitone, phenytoin, and topiramate 
have been shown to have adverse effects upon cognition, 
which is particularly relevant for people with ID [49]. Prescribing older AEDs including phenobarbitone and 
phenytoin is not advised for people with ID [47]. 
The prescription of multiple AEDs, at high doses, with rapid titration, is associated with an increased risk of 
adverse cognitive and behavioural effects [50]; AEDs should therefore be prescribed at the lowest possible 
dose with slow titration. This will help accurate assessment of efficacy and side effects. Slow titration will help 
identify the minimal therapeutic dose. If considering adding a new AED to treatment, it is advisable to do so 
before withdrawing the old AED. This will help assess the cause for changes in seizure control and side effect 
profile [47]. 
For individuals with particular risk factors including previous psychiatric history, history of behavioral 
disturbance, treatment-resistant epilepsy, and family history of psychiatric disorders, there should be close 
monitoring for the emergence of neuropsychiatric symptoms. 
These symptoms may emerge during any change in AED medication, if withdrawing AEDs with mood stabilizing 
effect (carbamazepine, oxcarbazepine, valproate, lamotrigine), or if seizure freedom is achieved [50]. 
 
3.2.2. Interictal psychiatric comorbidity 
The treatment of interictal psychiatric manifestations including depression, anxiety disorders, and psychotic 
illness will follow guidelines as advised for the general population. However, there are some specific 
considerations for people with epilepsy and ID. Psychological therapies, for example, may need to be adapted 
and tailored specifically to an individual's level of understanding and communication. The evidence for the use 
of psychological therapies for people with epilepsy and ID is limited with no randomized controlled trials 
available [35]. There is evidence to support the use of tailored cognitive behavioral therapy (CBT) in people 
with ID for the treatment of anxiety, depression, and psychosis [16]. Prior to the initiation of any therapy a 
‘step-wise’ approach 
with formal neuropsychological and metacognitive assessment is recommended. This will help to gain a 
baseline understanding of cognitive ability, skills, emotional regulation, and insight, all aspects relevant to 
successful CBT [51]. 
 
3.2.3. Pharmacological management 
3.2.3.1. Depression. If a depressive disorder is considered then the first step may be referral to specialist 
mental health services for assessment and diagnosis. The first line management of a depressive disorder may 
include supportive therapy and consideration for psychological therapy such as CBT where available [16]. If it is 
established that the depressive episode warrants pharmacological treatment then selective serotonin 
reuptake inhibitors (SSRIs) are considered first line therapy. Serotonin norepinephrine reuptake inhibitors 
(SNRIs) have also been shown be have no detrimental impact on seizure control at therapeutic doses. Older 
agents such as the tricyclic antidepressant clomipramine may reduce the seizure threshold [52]. There appears 
to be a dose-dependent relationship between the prescription of antidepressants and seizures. Therefore 
when prescribing, it is advised to start at a low dose with slow titration. When considering which SSRI to 
prescribe, it may be advised to consider alternatives to fluoxetine such as citalopram or sertraline. This is 
because fluoxetine has a long half-life and is associated with more drug interactions [47]. 
 
3.2.3.2. Psychosis. The treatment of interictal psychosis or psychotic disorders such as schizophrenia should 
follow usual treatment pathways as for the general population. It is well-understood that antipsychotic 
medications have the propensity to impact upon seizure control. In particular chlorpromazine and clozapine 
have been shown to demonstrate proconvulsive effects in patients with epilepsy [53]. Clozapine can cause 
epileptiform EEG changes and seizures even at therapeutic doses [54]. Rapid titration and high dose of 
clozapine may be the most detrimental to good seizure management [12]. A study examining the influence of 
antipsychotic drugs on seizures has highlighted that first generation antipsychotics have a slighter higher 
association with seizure risk. Among the second generation antipsychotic drugs, Clozapine has been associated 
with the highest incidence of seizures when compared with placebo, followed by olanzapine and then 
quetiapine [52]. Aripiprazole may have the lowest potential to induce seizures, and is worth considering first, if 
seizure control is paramount [55]. 
 
3.2.4. Behavioral disorders 
Behavioral assessment and intervention should form a core component of the management of a behavioral 
disorder according to NICE guideline NG11 [56]. A randomized, single-blind, controlled trial of specialist 
behavior therapy for challenging behavior in people with ID showed significant improvement in ABC scores and 
other measures of behavior [57]. Given the complexity of presentation of behavioral disorders in people with 
epilepsy and ID, this process would be best shared with specialist ID psychiatrist services [16]. 
 
3.2.5. Pharmacological management 
There is limited evidence to support using psychotropic medications to treat challenging behavior in people 
with ID. A randomized controlled trial assessing the efficacy of risperidone and haloperidol in the treatment of 
aggression in people with ID showed no benefit compared with placebo [58]. Despite this, a large proportion 
of people with ID are 
Treated with antipsychotic medication for challenging behaviour without 
a diagnosis of serious mental illness [59]. 
 
When psychotropicmedication for behavioral disturbances is necessary then prescription and monitoring 
should be done in liaison with specialist psychiatric services. The prescription of antipsychotic cmedication for 
challenging behavior should be short-term and monitored for efficacy. Target behaviors should be identified 
from the outset for treatment and monitored considering the multifactorial nature of behaviour [16]. As 
discussed, concerns will remain over the potential impact of the prescribed psychotropic medications on 
seizure control. 
 
3.2.6. Periictal disturbance and postictal psychosis 
Fear and anxiety can also be associated with seizures themselves either in the preictal or ictal period. 
Differentiation between these two presentations can be difficult but is important in terms of treatment 
decisions [12]. 
 
Postictal psychosis can severely affect quality of life and pose particular difficulties in management. Classically 
a postictal psychosis is observed after a symptom-free period following the seizure. This time lag can be 
anything from hours to seven days [60]. This disturbance is usually relatively short-lived; however, prolonged 
debilitating presentations may warrant antipsychotic treatment. The antipsychotic can then be reduced and 
discontinued gradually following improvement in symptoms [50] 
 
Improvement in seizure control will help reduce the likelihood of further postictal events, and so, treatment 
should be maximized. However, with seizure freedom comes the risk of so-called ‘forced-normalization’. This is 
a risk of developing potentially severe psychotic and affective symptoms with seizure remission in patients 
with complex treatment-resistant epilepsy. This may be more likely with certain AEDs and should be managed 
as with interictal disturbances [60]. 
 
4. Delivery of care — the role of the neurologist 
Epilepsy in people with ID is managed by various healthcare professionals including primary care physicians, 
specialist nurses, neurologists, psychiatrists, and neuropsychiatrists. Care pathways vary both within and 
between countries with limited guidance as to the appropriate care pathway for individuals. In the UK, 
multidisciplinary teams for people with ID tend to be based in the community where as neurological services 
tend to be hospital based. Two studies of English patients with learning disability and epilepsy found that 
around 40% received care for their epilepsy from a hospital-based neurology service [61,62]. People with ID 
and epilepsy managed primarily by neurologists had more neurological 
comorbidities while those managed by community ID teams had more psychiatric comorbidity [62]. 
Most neurologists with an interest in epilepsy will see patients with ID and should therefore be aware of the 
spectrum of psychiatric comorbidities in this population, how to screen for them, avoid them, and treat if 
appropriate. Neurologists may have the best skills to exclude and or diagnose other underlying conditions that 
can cause psychiatric features, e.g., limbic encephalitis or neurodegenerative disorders. Neurologists should 
also be able to manage psychiatric side effects of AEDs. 
Neurologists may lack specific training and competence in managing significant psychiatric comorbidities in 
epilepsy. A recent survey highlighted a lower level of self-perceived knowledge and confidence in dealing with 
psychiatric comorbidities and epilepsy when comparing neurologists to psychiatrists [63]. In the same survey 
only just over 20% of adult neurologists felt their knowledge of epilepsy and ID was good or very good 
compared with 70% of psychiatrists. Given this, it may be appropriate that patients with more complicated or 
severe psychiatric comorbidities are managed by psychiatrists/neuropsychiatrists. 
There is clearly therefore a need for greater support of neurologists both in terms of training and direct 
support form psychological services. This notwithstanding the neurologist has a current and important role in 
managing psychiatric comorbidities. This role can be divided into three areas of expertise. These three areas 
we describe below. 
  
Competency A. The neurologist and the assessment of psychiatric comorbidities. 
All neurologists should have the competency to identify the presence, or the suspicion of the presence of 
psychiatric disturbance, such as nonconvulsive status, infection, metabolic or toxic causes. Following this all 
neurologists should have the competency to 
refer for further psychiatric assessment or manage as in competencies 
B and C below. 
Competency B. The neurologist managing epilepsy-related psychiatric comorbidities. 
Following identification of epilepsy-related psychiatric comorbidity all neurologists will have the competency 
to alter AED medication if needed and to assess treatment options to reduce seizures or to manage 
neuropsychiatric side effects. 
Competency in managing postictal psychiatric symptoms will depend on training and experience. Where 
needed referral to psychiatric services should occur. 
Competency C. The treatment of psychiatric comorbidity. This is again an area for personal skill and 
experience. Many neurologists have experience in treating depression for example. However, most 
neurologists lack the skills necessary to treat psychosis and behavioral 
disturbance. The nature of psychiatric comorbidity, particularly challenging behavior needs the input of a 
multidisciplinary team. In this context, the neurologist best works as a source of guidance and skills to the 
team. 
 
5. Conclusions 
Psychiatric symptoms and behavioral disturbance are common in patients with epilepsy and ID and can be 
related to the epilepsy, epilepsy treatment, or other conditions or can occur as comorbid conditions. Careful 
assessment of psychiatric symptoms and behavioral disturbance are necessary to work out their etiology. 
Structured multidisciplinary assessment techniques can be a useful adjunct due to the complexity or etiology 
and comorbidities. Neurologists have a role in the multidisciplinary management of patients with ID and 
epilepsy with psychiatric comorbidities. Neurologist's skills may be particularly suited to screening for other 
conditions that may cause psychiatric symptoms, managing seizures, and changing AEDs if necessary. It might 
be more appropriate however for psychiatrists to advise on or manage psychiatric comorbidities, particularly if 
treatment with antipsychotic medication is warranted. 
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